There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Syndax Pharmaceuticals (SNDX – Research Report) and SQZ Biotechnologies (SQZ – Research Report) with bullish sentiments.
Syndax Pharmaceuticals (SNDX)
In a report issued on December 5, Robert Hazlett from BTIG reiterated a Buy rating on Syndax Pharmaceuticals, with a price target of $34.00. The company’s shares closed last Tuesday at $24.21.
According to TipRanks.com, Hazlett is a 3-star analyst with an average return of
Syndax Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $32.00, a 26.5% upside from current levels. In a report issued on December 5, H.C. Wainwright also maintained a Buy rating on the stock with a $31.00 price target.
See the top stocks recommended by analysts >>
SQZ Biotechnologies (SQZ)
BTIG analyst Thomas Shrader maintained a Buy rating on SQZ Biotechnologies yesterday and set a price target of $4.00. The company’s shares closed last Tuesday at $1.30.
According to TipRanks.com, Shrader is a 1-star analyst with an average return of
SQZ Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $13.00, which is a 766.7% upside from current levels. In a report issued on November 30, Brookline Capital Markets also maintained a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SNDX:
